Goldman Sachs’s Liminatus Pharma LIMN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-804
Closed -$4.44K – 7161
2026
Q2
$4.44K Buy
+804
New +$6.94K ﹤0.01% 6499

Other funds holding LIMN

Goldman Sachs's LIMN Position: Q3 2026 in Review

Goldman Sachs sold out of Liminatus Pharma (LIMN) in Q3 2026, closing a stake of 804 shares — an estimated $4.44K sold.

Goldman Sachs first reported a position in LIMN in Q2 2026 and held it in 1 quarter. The position peaked at $4.44K in Q2 2026. 10 funds tracked by Wall St. Rank hold LIMN as of Q3 2026.

  • Goldman Sachs reported no remaining Liminatus Pharma position as of Q3 2026 after selling out during the quarter.
  • Goldman Sachs sold 804 Liminatus Pharma shares in Q3 2026, an estimated $4.44K.
  • Goldman Sachs first reported a position in Liminatus Pharma in Q2 2026 and held it in 1 quarter.
  • Goldman Sachs's Liminatus Pharma position peaked at $4.44K in Q2 2026.
  • 10 funds tracked by Wall St. Rank held Liminatus Pharma as of Q3 2026.

Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.